Aminopterin dosage forms and methods for inflammatory disorders
There is disclosed dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Specifically, there is disclosed a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.
1. A method for treating an inflammatory disorder in a patient comprising administering at least four uninterrupted cycles of aminopterin or a pharmaceutically acceptable salt thereof in a therapeutically effective amount, wherein the inflammatory disorder is selected from the group consisting of bronchopulmonary dysplasia, systemic lupus erythematosus (SLE), graft-versus-host-disease (GVHD), polymyositis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, atopic dermatitis, dermatitis, multiple sclerosis, inflammatory bowel disease, and canine atopic dermatitis, wherein each uninterrupted cycle has from 1 to 5 aminopterin doses, and wherein a duration between a last dose of one uninterrupted cycle and a first dose of a next uninterrupted cycle does not exceed 21 days.
2. The method for treating an inflammatory disorder in a patient of claim 1 wherein the uninterrupted cycle of aminopterin treatment comprises a plurality of doses of aminopterin.
3. The method for treating an inflammatory disorder in a patient of claim 1 wherein the therapeutically effective amount of aminopterin in each uninterrupted cycle is not greater than 0.07 mg aminopterin per kilogram of patient body weight.
4. The method for treating an inflammatory disorder in a patient of claim 1 wherein the uninterrupted cycle of aminopterin comprises administering aminopterin in a tablet, comprising no more than ten tablets and wherein the tablet contains from about 0.0175 mg to about 7 mg aminopterin.
5. The method for treating an inflammatory disorder in a patient of claim 4 wherein the tablet contains from about 0.0175 mg to about 0.5 mg aminopterin.
6. The method for treating an inflammatory disorder in a patient of claim 5 wherein the tablet contains from about 0.025 to about 0.5 mg aminopterin.
7. A method for inhibiting an enzyme dihydrofolate reductase (DHFR) in vivo, comprising administering an effective amount of aminopterin or a salt thereof, wherein the effective amount of aminopterin is administered in uninterrupted cycles and the dose of aminopterin per uninterrupted cycle is from about 0.0005 to about 0.07 mg per kilogram of body weight, wherein each uninterrupted cycle has from 1 to 5 aminopterin doses, and wherein a duration between a last dose of one uninterrupted cycle and a first dose of a next uninterrupted cycle does not exceed 21 days.
8. The method for inhibiting the enzyme DHFR in vivo of claim 7 , wherein the percent inhibition of DHFR is greater than 5%.
9. The method for inhibiting the enzyme DHFR in vivo of claim 7 , further comprising treating an inflammatory disorder, wherein the inflammatory disorder is selected from the group consisting of systemic lupus erythematosus (SLE), graft-versus-host-disease (GVHD), polymyositis, rheumatoid arthritis, other forms of arthritis, psoriasis, atopic dermatitis, multiple sclerosis, Crohn's Disease, inflammatory bowel disease, and combinations thereof.
10. A method for treating canine atopic dermatitis and bronchopulmonary dysplasia, comprising administering at least four uninterrupted cycles of an effective amount of aminopterin or methotrexate, or a pharmaceutically acceptable salt thereof, wherein each uninterrupted cycle has from 1 to 5 aminopterin doses, and wherein a duration between a last dose of one uninterrupted cycle and a first dose of a next uninterrupted cycle does not exceed 21 days.
11. The method for treating canine atopic dermatitis and bronchopulmonary dysplasia of claim 10 wherein the drug is aminopterin.